

Alessandra Emilia Savarino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7651973/publications.pdf>

Version: 2024-02-01

50
papers

3,600
citations

218381

26
h-index

197535

49
g-index

54
all docs

54
docs citations

54
times ranked

6907
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial. <i>AIDS Research and Therapy</i> , 2022, 19, 2.	0.7	3
2	The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication <i>in Vitro</i> and Decreases Viral Titers and Disease Progression in Syrian Hamsters. <i>MBio</i> , 2022, 13, e0370521.	1.8	22
3	Glycolysis downregulation is a hallmark of HIV-1 latency and sensitizes infected cells to oxidative stress. <i>EMBO Molecular Medicine</i> , 2021, 13, e13901.	3.3	30
4	NHC-gold compounds mediate immune suppression through induction of AHR-TGF β 1 signalling <i>in vitro</i> and in scurfy mice. <i>Communications Biology</i> , 2020, 3, 10.	2.0	14
5	Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020, 45, 715-723.	0.6	20
6	A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106078.	1.1	37
7	Alterations of redox and iron metabolism accompany the development of HIV-1 latency. <i>EMBO Journal</i> , 2020, 39, e102209.	3.5	37
8	Potential impact of the antirheumatic agent auranofin on proviral HIV-1 DNA in individuals under intensified antiretroviral therapy: Results from a randomised clinical trial. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 592-600.	1.1	29
9	Crossroads of Cancer and HIV-1: Pathways to a Cure for HIV. <i>Frontiers in Immunology</i> , 2019, 10, 2267.	2.2	12
10	Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models. <i>Viruses</i> , 2016, 8, 322.	1.5	227
11	Dual targeting of the thioredoxin and glutathione systems in cancer and HIV. <i>Journal of Clinical Investigation</i> , 2016, 126, 1630-1639.	3.9	139
12	Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS. <i>Retrovirology</i> , 2015, 12, 51.	0.9	48
13	Cell-mediated anti-HIV-1 immunity in pharmacologically induced functional cure of simian AIDS: a "bottleneck effect"? <i>Journal of Medical Primatology</i> , 2015, 44, 227-240.	0.3	4
14	Two-Year Follow-Up of Macaques Developing Intermittent Control of the Human Immunodeficiency Virus Homolog Simian Immunodeficiency Virus SIVmac251 in the Chronic Phase of Infection. <i>Journal of Virology</i> , 2015, 89, 7521-7535.	1.5	20
15	Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS. <i>Retrovirology</i> , 2013, 10, 71.	0.9	30
16	A cure for AIDS: a matter of timing?. <i>Retrovirology</i> , 2013, 10, 145.	0.9	11
17	A Highly Intensified ART Regimen Induces Long-Term Viral Suppression and Restriction of the Viral Reservoir in a Simian AIDS Model. <i>PLoS Pathogens</i> , 2012, 8, e1002774.	2.1	70
18	Therapeutic imprinting of the immune system: towards a remission of AIDS in primates?. <i>Retrovirology</i> , 2012, 9, 75.	0.9	3

#	ARTICLE	IF	CITATIONS
19	Use of chloroquine in viral diseases. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 653-654.	4.6	29
20	Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. <i>Aids</i> , 2011, 25, 1347-1356.	1.0	74
21	Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. <i>Retrovirology</i> , 2010, 7, 21.	0.9	36
22	Plasmeprin 4-Deficient <i>Plasmodium berghei</i> Are Virulence Attenuated and Induce Protective Immunity against Experimental Malaria. <i>American Journal of Pathology</i> , 2010, 176, 205-217.	1.9	105
23	Evaluation of the antiretroviral effects of a PEG-conjugated peptide derived from human CD38. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 141-152.	1.5	5
24	Characterization of the serological response to phospholipase D protein of <i>Chlamydomonas pneumoniae</i> in patients with acute coronary syndromes. <i>Microbes and Infection</i> , 2009, 11, 367-373.	1.0	5
25	"Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. <i>Retrovirology</i> , 2009, 6, 52.	0.9	100
26	Non-Cancer Uses of Histone Deacetylase Inhibitors: Effects on Infectious Diseases and Hemoglobinopathies. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 272-291.	1.0	44
27	Response of Feline Immunodeficiency Virus (FIV) to Tipranavir May Provide New Clues for Development of Broad-Based Inhibitors of Retroviral Proteases Acting on Drug-Resistant HIV-1. <i>Current HIV Research</i> , 2008, 6, 306-317.	0.2	12
28	On the use of chloroquine for chikungunya. <i>Lancet Infectious Diseases</i> , The, 2007, 7, 633.	4.6	18
29	Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses. <i>Virology Journal</i> , 2007, 4, 39.	1.4	66
30	In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. <i>Retrovirology</i> , 2007, 4, 21.	0.9	65
31	Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to redesign antiretroviral treatment for feline AIDS. <i>Retrovirology</i> , 2007, 4, 79.	0.9	37
32	Risks and benefits of chloroquine use in anticancer strategies. <i>Lancet Oncology</i> , The, 2006, 7, 792-793.	5.1	46
33	New insights into the antiviral effects of chloroquine. <i>Lancet Infectious Diseases</i> , The, 2006, 6, 67-69.	4.6	458
34	A historical sketch of the discovery and development of HIV-1 integrase inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 1507-1522.	1.9	108
35	Quinoline antimalarials as investigational drugs for HIV-1/AIDS: in vitro effects on HIV-1 replication, HIV-1 response to antiretroviral drugs, and intracellular antiretroviral drug concentrations. <i>Drug Development Research</i> , 2006, 67, 806-817.	1.4	10
36	Potential therapies for coronaviruses. <i>Expert Opinion on Therapeutic Patents</i> , 2006, 16, 1269-1288.	2.4	9

#	ARTICLE	IF	CITATIONS
37	Role of Lymphocyte Multidrug Resistance Protein 1 in HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 40, 257-266.	0.9	16
38	Aspartic Proteases of <i>Plasmodium falciparum</i> as the Target of HIV-1 Protease Inhibitors. <i>Journal of Infectious Diseases</i> , 2005, 191, 1381-1382.	1.9	21
39	Expanding the frontiers of existing antiviral drugs: Possible effects of HIV-1 protease inhibitors against SARS and avian influenza. <i>Journal of Clinical Virology</i> , 2005, 34, 170-178.	1.6	43
40	Candidiasis and HIV-Protease Inhibitors: The Expected and the Unexpected. <i>Current Medicinal Chemistry Immunology, Endocrine & Metabolic Agents</i> , 2004, 4, 49-59.	0.2	8
41	Anti-HIV Effects of Chloroquine. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2004, 35, 223-232.	0.9	104
42	Effects of chloroquine on viral infections: an old drug against today's diseases. <i>Lancet Infectious Diseases</i> , The, 2003, 3, 722-727.	4.6	1,022
43	Human CD38 interferes with HIV-1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120. <i>FASEB Journal</i> , 2003, 17, 1-20.	0.2	28
44	Role of FAS in HIV Infection. <i>Current HIV Research</i> , 2003, 1, 405-417.	0.2	25
45	Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. <i>Aids</i> , 2001, 15, 2221-2229.	1.0	105
46	Role of CD38 in HIV-1 infection: an epiphenomenon of T-cell activation or an active player in virus/host interactions?. <i>Aids</i> , 2000, 14, 1079-1089.	1.0	111
47	Expression of prolactin and prolactin receptors by non-Hodgkin's lymphoma cells. <i>International Journal of Cancer</i> , 2000, 85, 124-130.	2.3	26
48	Effects of the human CD38 glycoprotein on the early stages of the HIV-1 replication cycle. <i>FASEB Journal</i> , 1999, 13, 2265-2276.	0.2	16
49	Iron metabolism and HIV infection: reciprocal interactions with potentially harmful consequences?. , 1999, 17, 279-287.		78
50	The Biochemistry of Gene Therapy for AIDS. <i>Clinical Chemistry and Laboratory Medicine</i> , 1998, 36, 205-10.	1.4	3